Entera Bio Ltd. 8-K

What Happened
Entera Bio Ltd. announced on April 2, 2026 the closing of a private placement with funds affiliated with BVF Partners LP raising approximately $10.0 million. The purchaser bought 7,827,789 units at about $1.2775 per unit; each unit includes one ordinary share (or a pre-funded warrant in lieu of the share) and one warrant to buy 1.5 ordinary shares. The company said net proceeds will support initiation of its Phase 3 registrational study of EB613 in postmenopausal women with osteoporosis and for general working capital.

Key Details

• Units issued: 7,827,789 units for aggregate proceeds of ~ $10.0M (≈ $1.2775 per unit). Closing date: April 2, 2026.
• Warrant terms: Pre-Funded Warrants exercise price NIS 0.0000769, immediately exercisable, no expiration; Ordinary Share Warrants exercise price $1.24, exercisable six months after closing, expire five years from issuance.
• Potential additional proceeds: If all Ordinary Share Warrants are exercised for cash (and registration permits), Entera would receive approximately $14.5M more.
• Ownership limits & registration: Both warrant types include a 4.99% ownership cap (with optional increases up to 19.99%). The company agreed to file a resale registration statement within 30 days of closing. Securities sold under Section 4(a)(2) exemption to an accredited investor.

Why It Matters
This financing provides near-term cash to advance Entera’s planned Phase 3 study of EB613—an important milestone for the company’s lead program—and extends its working capital runway without a public offering. Investors should note dilution from issued shares/warrants, the potential for up to ~$14.5M additional cash if warrants are exercised for cash, and the 4.99% ownership caps that limit immediate concentration by the purchaser. The resale registration commitment will affect when warrant holders can sell shares publicly.